• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Meg Bryant

Articles by Meg Bryant

FDA greenlights Abbott's Alinity s blood, plasma screening system

July 12, 2019
By Meg Bryant

Orchestra Biomed raises $34M to advance circulatory solutions

July 11, 2019
By Meg Bryant
New Hope, Pa.-based Orchestra Biomed Inc. scooped up $34 million in a series B-1 preferred stock financing led by Perceive Advisors, RTW Investments and Soleus Capital. The funds will be used to advance development of the company's Backbeat cardiac neuromodulation therapy (CNT) system, to support commitments to Orchestra's strategic global partnership with Tokyo-based Terumo Corp. for the development and marketing of the Virtue sirolimus-eluting balloon (SEB) and to grow the company's product pipeline and pursue future collaborations. Terumo and existing investors from Sternaegis Ventures also participated in the round.
Read More

Procyrion scoops up $30M in series D round for Aortix pump

July 10, 2019
By Meg Bryant

New data bolsters evidence on Medtronic's less-invasive Heartware HVAD technique

July 9, 2019
By Meg Bryant
Two years after receiving Medtronic plc's Heartware ventricular assist device (HVAD) via a less-invasive implant procedure, 95% of patients were free from disabling stroke, according to the Dublin-based company. Adverse events, if they did occur, were mostly seen within the first 30 days following implant, with total strokes occurring at only 0.05 events per patient year (EPPY) in years one to two post-implant. Results of the LATERAL clinical trial were presented at the American Society for Artificial Internal Organs 65th annual conference in San Francisco.
Read More

Say cheese: Home tests powered by nano chip and iPhone camera

July 8, 2019
By Meg Bryant

Biocorp in talks to add its CE marked Mallya device to Sanofi's diabetes care platform

July 5, 2019
By Meg Bryant
Less than a month after securing CE marking for the Mallya smart sensor cap for injection pens, Biocorp SA, of Issoire, France, is in exclusive negotiations with Paris-based Sanofi SA, to deploy the device on Sanofi's integrated diabetes care platform. Final terms of the arrangement are still being hammered out, but it is expected to include an initial payment of €4 million (US$4.5 million) to Biocorp to advance product development and related activities.
Read More

Varian boosts cancer portfolio with acquisition of embolic bead products

July 3, 2019
By Meg Bryant
Varian Medical Systems Inc., of Palo Alto, Calif., continues its recent spending spree, reporting Tuesday that it has signed an agreement to acquire Marlborough, Mass.-based Boston Scientific Corp.'s line of embolic bead products for $90 million. The proposed purchase of the drug-loadable microsphere and bland embolic bead portfolio comes on the heels of Varian's June acquisitions of Austin-based Endocare Inc. and Hangzhou, China-based Alicon, and aims to boost Varian's footprint in the global interventional oncology market.
Read More

Vaxess closes final tranche of $8.2M series A round for silk-based smart release patch

July 2, 2019
By Meg Bryant

Veracyte launches improved lung cancer risk tech in U.S.

July 1, 2019
By Meg Bryant

Natera eyes improving kidney transplant survival using Prospera cell-free DNA assay

June 27, 2019
By Meg Bryant
San Carlos, Calif.-based Natera Inc. has kicked off a prospective nationwide registry study for kidney transplant recipients to look at changes in biopsy usage and clinical outcomes associated with use of its Prospera kidney transplant rejection assay. The Proactive study, which will involve 3,000 kidney transplant patients from the time of surgery, will follow most patients for three years and a subset of high-risk patients for five years. The overarching goal of the study is to improve detection of active rejection and improve long-term patient outcomes with use of physician-prescribed Prospera.
Read More
Previous 1 2 … 65 66 67 68 69 70 71 72 73 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • Boston Scientific Acurate Prime Aortic Valve System

    In TAVR setback, Boston Sci pulls plug on Acurate valves

    BioWorld MedTech
    Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe